Eupraxia Pharmaceuticals Inc News

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR

MT NewswiresOct 15 07:31 ET

Eupraxia Pharmaceuticals Details Executive Appointments

MT NewswiresOct 2 17:25 ET

Eupraxia Pharmaceuticals Brief: Appointing Chief Scientific Officer Amanda Malone, as Chief Operating and Scientific Officer, and Rahul Sarugaser, as Executive Vice President of Corporate Development

MT NewswiresOct 2 17:02 ET

Eupraxia Pharmaceuticals Reports Positive Data From RESOLVE Trial

MT NewswiresSep 11 08:15 ET

Eupraxia's EP-104GI Shows Promise in EoE Trial

TipRanksSep 11 07:27 ET

Eupraxia Pharmaceuticals Brief: Announcing Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

MT NewswiresSep 11 07:02 ET

Eupraxia Pharmaceuticals Announces Data From RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

PR NewswireSep 11 07:00 ET

Press Release: Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Dow JonesAug 7 17:00 ET

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

PR NewswireJul 8 07:00 ET

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

PR NewswireJul 3 17:00 ET

Eupraxia Pharmaceuticals Announces Voting Results From Annual General and Special Meeting of Shareholders

Stockhouse Jun 6 17:00 ET

Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data From the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

MT NewswiresJun 5 07:02 ET

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

Stockhouse May 22 07:00 ET

Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%

MT NewswiresMay 21 17:13 ET

Eupraxia Pharmaceuticals to Present Initial Results From Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

Stockhouse May 14 07:00 ET

Press Release: Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesMay 8 17:03 ET

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Stockhouse May 8 17:03 ET

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Stockhouse Apr 11 07:00 ET

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Stockhouse Apr 8 07:00 ET

Stocks in Play: Eupraxia Pharmaceuticals Inc.\

Baystreet.caApr 5 10:00 ET